Arabic Arabic English English French French German German
dark

Public Meeting on Patient Focused Drug Development for Idiopathic Pulmonary Fibrosis Part 2

On September 26, 2014, FDA hosted a public meeting on Patient-Focused Drug Development for Idiopathic Pulmonary Fibrosis. FDA was interested in obtaining patient perspectives on the impact of Idiopathic Pulmonary Fibrosis on daily life and patient views on treatment approaches. For more information, visit https://go.usa.gov/x6kc9.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Study examines COVID-19 among patients receiving home dialysis

Next Post

Oregon House Passes Telemedicine Reimbursement Bill to Promote Safe Access to Care

Related Posts
Total
0
Share